Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 20/20 | 1.00 |
| ▸ | JAK2 | O60674 | 19/20 | 1.00 |
| ▸ | JAK1 | P23458 | 16/20 | 1.00 |
| ▸ | TYK2 | P29597 | 2/20 | 0.68 |
| ▸ | MAP4K3 | Q8IVH8 | 1/20 | 0.54 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13398277 | 0.92 | JAK2 (0.85) | JAK3JAK2JAK1TYK2 | |
| SCHEMBL2104138 | 0.89 | JAK2 (0.80) | JAK3JAK2JAK1TYK2 | |
| SCHEMBL2105157 | 0.88 | JAK1 (0.90) | JAK3JAK2JAK1TYK2 | |
| SCHEMBL2106261 | 0.88 | JAK1 (0.90) | JAK3JAK2JAK1TYK2 | |
| SCHEMBL12833306 | 0.87 | JAK3 (0.77) | JAK3JAK2JAK1TYK2MAP4K3 | |
| SCHEMBL2105305 | 0.87 | JAK2 (0.77) | JAK3JAK2JAK1TYK2 | |
| SCHEMBL2102281 | 0.87 | JAK2 (0.77) | JAK3JAK2JAK1TYK2 | |
| SCHEMBL3314602 | 0.87 | JAK2 (0.80) | JAK3JAK2JAK1 | |
| SCHEMBL3316455 | 0.87 | JAK2 (0.80) | JAK3JAK2JAK1 | |
| SCHEMBL13398165 | 0.86 | JAK2 (0.76) | JAK3JAK2JAK1TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163767-B2 | Heterocyclic Janus Kinase 3 inhibitors | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | claimed |
| US-20090264399-A1 | HETEROCYCLIC JANUS KINASE 3 INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2009-10-22 | — | — | US | claimed |
| US-8163767-B2 | Heterocyclic Janus Kinase 3 inhibitors | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| EP-2251341-A1 | Heterocyclic Janus kinase 3 inhibitors | Astellas Pharma Inc. (JP) | 2010-11-17 | — | — | EP | disclosed |
| US-20090264399-A1 | HETEROCYCLIC JANUS KINASE 3 INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264399-A1 | HETEROCYCLIC JANUS KINASE 3 INHIBITORS | JAK3, JAK2, JAK1 | JAK3 1/4885JAK2 2/4885JAK1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.